Provided by Tiger Fintech (Singapore) Pte. Ltd.

United Therapeutics

316.38
+0.47100.15%
Volume:236.07K
Turnover:75.61M
Market Cap:14.21B
PE:12.84
High:323.43
Open:313.93
Low:313.93
Close:315.91
Loading ...

Press Release: United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025

Dow Jones
·
19 Feb

United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings?

StockStory
·
14 Feb

Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength?

Zacks
·
13 Feb

Ardelyx (ARDX) Earnings Expected to Grow: Should You Buy?

Zacks
·
13 Feb

United Therapeutics: Growth Prospects and Financial Performance Support ‘Buy’ Rating

TIPRANKS
·
13 Feb

United Therapeutics Corporation (UTHR): A Cheap Biotech Stock to Invest In Now

Insider Monkey
·
12 Feb

UTHR or ZTS: Which Is the Better Value Stock Right Now?

Zacks
·
08 Feb

UBS Adjusts Price Target on United Therapeutics to $460 From $475, Keeps Buy Rating

MT Newswires Live
·
07 Feb

United Therapeutics Completes Patient Enrollment for Another Trial of Idiopathic Pulmonary Fibrosis Treatment

MT Newswires Live
·
04 Feb

United Therapeutics Corporation's (NASDAQ:UTHR) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Simply Wall St.
·
04 Feb

BRIEF-United Therapeutics Fully Enrolls Teton 1 Study Of Inhaled Treprostinil For Idiopathic Pulmonary Fibrosis

Reuters
·
04 Feb

United Therapeutics: TETON 1 study of nebulized Tyvaso for IPF fully enrolled

TIPRANKS
·
04 Feb

United Therapeutics Corp - Top Line Data Expected in First Half of 2026

THOMSON REUTERS
·
04 Feb

United Therapeutics Corporation Announces Full Enrollment of the Teton 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

THOMSON REUTERS
·
04 Feb

United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

Business Wire
·
04 Feb

BofA Adjusts Price Target on United Therapeutics to $328 From $327

MT Newswires Live
·
03 Feb